Mylan N.V. (NASDAQ:MYL) saw some unusual options trading activity on Thursday. Stock investors bought 15,303 put options on the stock. This is an increase of approximately 638% compared to the typical volume of 2,073 put options.
Mylan N.V. (NASDAQ:MYL) traded up 0.30% during midday trading on Thursday, reaching $30.56. 8,816,475 shares of the company’s stock were exchanged. Mylan N.V. has a 52 week low of $29.39 and a 52 week high of $49.42. The firm’s 50 day moving average is $36.59 and its 200 day moving average is $38.90. The firm has a market capitalization of $16.39 billion, a price-to-earnings ratio of 24.70 and a beta of 1.27.
Mylan N.V. (NASDAQ:MYL) last announced its earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.18 by $0.08. The business had revenue of $2.96 billion for the quarter, compared to analyst estimates of $3 billion. Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. The company’s quarterly revenue was up 15.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.16 earnings per share. On average, equities analysts anticipate that Mylan N.V. will post $4.51 earnings per share for the current year.
In other Mylan N.V. news, insider Anthony Mauro sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, June 9th. The shares were sold at an average price of $40.00, for a total value of $400,000.00. Following the completion of the transaction, the insider now owns 140,653 shares of the company’s stock, valued at approximately $5,626,120. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, President Rajiv Malik sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $40.00, for a total transaction of $1,000,000.00. Following the completion of the sale, the president now owns 799,855 shares of the company’s stock, valued at $31,994,200. The disclosure for this sale can be found here. 0.69% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. WINTON GROUP Ltd purchased a new position in Mylan N.V. during the second quarter valued at approximately $303,000. Gofen & Glossberg LLC IL increased its position in Mylan N.V. by 2.4% in the second quarter. Gofen & Glossberg LLC IL now owns 15,194 shares of the company’s stock valued at $590,000 after buying an additional 360 shares in the last quarter. Wealthsource Partners LLC increased its position in Mylan N.V. by 1.9% in the second quarter. Wealthsource Partners LLC now owns 9,330 shares of the company’s stock valued at $362,000 after buying an additional 177 shares in the last quarter. Verition Fund Management LLC boosted its stake in shares of Mylan N.V. by 17.9% in the second quarter. Verition Fund Management LLC now owns 19,429 shares of the company’s stock valued at $754,000 after buying an additional 2,956 shares during the last quarter. Finally, Cypress Capital Group bought a new stake in shares of Mylan N.V. during the second quarter valued at about $369,000. 71.57% of the stock is owned by hedge funds and other institutional investors.
A number of equities research analysts have recently weighed in on MYL shares. UBS AG restated a “buy” rating and issued a $46.00 price objective (down from $50.00) on shares of Mylan N.V. in a report on Thursday, August 10th. Citigroup Inc. upgraded shares of Mylan N.V. from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $36.00 to $42.00 in a report on Wednesday. Morgan Stanley lowered their price target on shares of Mylan N.V. from $52.00 to $36.00 and set an “equal weight” rating for the company in a report on Monday, August 7th. Zacks Investment Research upgraded shares of Mylan N.V. from a “sell” rating to a “hold” rating in a report on Tuesday, June 20th. Finally, ValuEngine lowered shares of Mylan N.V. from a “buy” rating to a “hold” rating in a report on Wednesday, June 14th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $47.73.
TRADEMARK VIOLATION NOTICE: This story was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://stocknewstimes.com/2017/08/17/mylan-n-v-sees-unusually-high-options-volume-myl-updated-updated-updated.html.
Mylan N.V. Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.
